Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA) for Emgality (galcanezumab) as a preventive treatment for migraines in adults.
Emgality, a monoclonal antibody that selectively targets calcitonin gene-related peptide (CGRP), was initially approved by the U.S. FDA in September 2018 for migraine prevention and later in June 2019 for treating episodic cluster headaches in adults. In China, migraine headaches affect nearly one in ten individuals, with an estimated 130 million prevalent cases, predominantly among women. Notably, Novartis’s erenumab is already registered in China for the preventive treatment of adult migraines.- Flcube.com
